Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Astria Therapeutics, Inc. (ATXS : NSDQ)

• Company Description    Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics, formerly known as Catabasis Pharmaceuticals Inc., is based in BOSTON. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $6.67 Daily Weekly Monthly 20 Day Moving Average: 330,899 shares Shares Outstanding: 56.43 (millions) Market Capitalization: $376.42 (millions) Beta: 0.41 52 Week High: $12.92 52 Week Low: $3.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.11% 14.65% 12 Week 65.10% 38.87% Year To Date -25.39% -30.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 22 Boston Wharf Road 10th Floor - Boston,MA 02210 USA ph: 617-349-1971 fax: 617-273-2637 investors@astriatx.com http://www.astriatx.com

• General Corporate Information    Officers Jill C. Milne - President and Chief Executive Officer and Director Kenneth Bate - Chairman Noah Clauser - Chief Financial Officer and Treasurer Sunil Agarwal - Director Joanne Beck - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04635X102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 56.43 Most Recent Split Date: 8.00 (0.17:1) Beta: 0.41 Market Capitalization: $376.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.62 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.94 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -52.63% vs. Previous Quarter: -31.82% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -47.18 12/31/24 - -37.92 ROA 06/30/25 - - 03/31/25 - -31.26 12/31/24 - -25.99 Current Ratio 06/30/25 - - 03/31/25 - 17.39 12/31/24 - 17.49 Quick Ratio 06/30/25 - - 03/31/25 - 17.39 12/31/24 - 17.49 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.44 12/31/24 - 3.97 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 32.95 12/31/24 - 29.86

Powered by Zacks Investment Research ©